For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
PE 22-28 is a synthetic 7-amino acid peptide derived from positions 22 to 28 of the sortilin propeptide (PE). It is the most potent known selective TREK-1 potassium channel antagonist, with an IC50 of 0.12 nM versus 40 to 60 nM for its parent compound spadin, and produces antidepressant-like effects within 4 days in mouse behavioral models versus 21 days for fluoxetine. All evidence is preclinical from a single French research group. No human has received PE 22-28 in a clinical trial.
PE 22-28 is circulating in the research peptide community as a rapid-acting antidepressant with clinical data. Both characterizations require precise qualification.
On the rapid-acting antidepressant claim: the preclinical evidence is genuine and methodologically careful. The primary paper (Djillani et al., 2017, Frontiers in Pharmacology) is peer-reviewed, from a CNRS research group at Universite Cote d'Azur with a decade-long track record on the TREK-1/spadin axis, and the results in mouse behavioral models are replicated across multiple tests. The effect appears within 4 days in mice versus 21 days for fluoxetine in the same models. That is a real preclinical finding.
On the clinical data claim: the Devader 2017 study (Journal of Affective Disorders) measured endogenous PE peptide levels in the serum of 37 MDD patients and found they were lower than in 49 healthy controls, partially restored after 12 weeks of standard antidepressant treatment. This is a biomarker observation in humans, not administration of PE 22-28 to humans. No human has received PE 22-28 as a therapeutic intervention in any published study. Conflating endogenous PE serum measurement with a therapeutic trial of synthetic PE 22-28 is a category error that appears repeatedly in vendor copy and must be corrected.
PE 22-28 has never been administered to a human being in a controlled study. No Phase 1 safety data exists. The TREK-1 mechanism is novel and the preclinical signals are interesting, but the entire evidence base consists of mouse experiments from a single research group with no independent replication.
PE 22-28 is a synthetic 7-amino acid peptide representing positions 22 through 28 of PE, a naturally occurring 44-amino acid precursor peptide liberated during intracellular maturation of sortilin (neurotensin receptor-3, NTSR3) by the enzyme furin. PE can be measured in human serum. Sortilin is expressed throughout the brain including hippocampus, cortex, and hypothalamus, and physically interacts with the TREK-1 potassium channel in neurons.
The scientific lineage traces to Heurteaux et al. (2006, Nature Neuroscience), which showed that mice lacking the TREK-1 gene (KCNK2) are resistant to depression-like behaviors across five behavioral models with enhanced serotonergic neurotransmission and hippocampal neurogenesis. This established TREK-1 as a viable antidepressant target. Spadin (PE 12-28), a 17-amino acid PE fragment, was subsequently identified as an endogenous TREK-1 blocker with fast antidepressant properties in mice (Mazella et al., 2010, PLoS Biology) but with a short in vivo half-life of approximately 7 hours.
The Universite Cote d'Azur group then systematically screened spadin blood degradation products and shorter analogs to improve stability. PE 22-28, the 7-amino acid C-terminal fragment of spadin, emerged as the shortest sequence retaining TREK-1 blockade activity, with IC50 of 0.12 nM versus 40 to 60 nM for spadin, and in vivo activity lasting more than 24 hours versus 7 hours for spadin. Modified analogs G/A-PE 22-28 (Gly22 replaced by Ala22) and biotin-G/A-PE 22-28 showed IC50 values of 0.10 nM and 1.2 nM respectively, representing 400-fold and 33-fold improvements over spadin.
PE 22-28 is a selective TREK-1 potassium channel antagonist. TREK-1 (TWIK-related potassium channel 1, gene KCNK2) is a two-pore domain (K2P) background potassium channel expressed in hippocampal pyramidal neurons, serotonergic neurons of the dorsal raphe nucleus, and throughout the cortex. Background K2P channels set the resting membrane potential by providing a constitutive outward potassium current; pharmacological blockade raises membrane excitability.
When PE 22-28 blocks TREK-1, the net effect is membrane depolarization in TREK-1-expressing neurons, increased neuronal excitability, and enhanced serotonergic neurotransmission. In the dorsal raphe nucleus specifically, TREK-1 blockade increases the firing rate of serotonin (5-HT) neurons, providing the mechanistic link to antidepressant efficacy. This is mechanistically upstream of SSRIs: rather than blocking serotonin reuptake, PE 22-28 increases serotonergic neuron firing rate.
Downstream consequences include activation of CREB phosphorylation, induction of hippocampal neurogenesis, and upregulation of BDNF, PSD-95 (postsynaptic density protein 95 kDa), and synapsin. These are established markers of antidepressant action and explain the rapid behavioral effects in preclinical models.
IC50 of PE 22-28 for TREK-1 is 0.12 nM versus 40 to 60 nM for parent spadin, a 300 to 500-fold potency improvement. Specificity is high: PE 22-28 does not inhibit related K2P channels TREK-2, TRAAK, TRESK, or TASK-1 at tested concentrations.
A note on mechanism nomenclature in the wellness community: several vendors describe PE 22-28 as a BDNF mimetic that directly activates TrkB receptors. This characterization lacks peer-reviewed support in the primary literature. BDNF elevation observed in mouse studies is most accurately described as a downstream consequence of TREK-1 blockade and neurogenesis induction, not direct TrkB agonism.
In Djillani et al. (2017), mice treated with PE 22-28 or modified analogs showed significant reductions in immobility time in the forced swim test (FST). After 4-day sub-chronic treatment, PE 22-28 significantly reduced latency to eat in the novelty suppressed feeding test (NSFT), which has greater construct validity for antidepressant-relevant behavior than FST alone.
Hippocampal neurogenesis by BrdU labeling: PE 22-28 induced neurogenesis after only 4 days, versus 21 days for fluoxetine in the same laboratory's prior work. Synaptogenesis markers PSD-95 and synapsin were increased in mouse cortical neurons. In vivo half-time effects: approximately 14 to 17 hours for PE 22-28 versus 7 hours for parent spadin.
Multi-route efficacy: antidepressant-like effects were observed with intraperitoneal, intravenous, and gavage (oral tube) administration. The gavage result is a preliminary indicator that oral delivery may be feasible, though human oral bioavailability remains uncharacterized.
The preclinical antidepressant evidence is methodologically careful, replicated across multiple behavioral tests, and mechanistically coherent with the broader TREK-1 literature. The rapid neurogenesis induction (4 days vs. 21 days for SSRIs) is a genuinely compelling preclinical observation. Limitations: entire evidence base from a single research group with no independent replication; no human Phase 1 trial conducted or registered; FST and NSFT have known limitations predicting human antidepressant response.
Devader et al. (2017) measured serum PE and spadin concentrations in 37 MDD patients versus 49 healthy controls. Serum PE was significantly lower in MDD patients. After 12 weeks of standard antidepressant pharmacotherapy, PE levels were partially but significantly restored in treatment-responder patients, correlating with clinical mood improvement. Non-responders did not show PE restoration.
Roulot et al. (2018) found that TRD patients who failed pharmacotherapy but responded to ECT showed a significant increase in serum PE levels one month after ECT, correlating with clinical improvement (MADRS). This suggests endogenous PE may serve as a state-dependent biomarker of depression severity and treatment response.
These studies measure naturally occurring PE peptide in human blood. They support the hypothesis that the sortilin-TREK-1 pathway is relevant to human depression pathophysiology. They do not establish that synthetic PE 22-28 is efficacious or safe when administered to humans. This distinction is consistently misrepresented in vendor content where these studies are cited as clinical evidence for PE 22-28 therapy.
This is observational biomarker research in humans, not a PE 22-28 therapeutic intervention study. Both studies are small (n=37 and TRD cohort), single-center, from the same French-Italian collaboration. The authors note larger independent studies are needed to validate PE as a reliable depression biomarker. The findings strengthen mechanistic rationale for PE 22-28 development but are not clinical efficacy data.
Pietri et al. (2019) provided the first direct evidence for PE 22-28 in stroke and post-stroke depression. In a mouse MCAO model, treatment with PE 22-28 analogs reduced ischemic damage, attenuated post-stroke depressive behaviors, and was associated with increased neurogenesis and synaptogenesis in the hippocampus.
The mechanistic rationale is that TREK-1 is overexpressed in brain tissue after ischemia, potentially contributing to the post-stroke depression phenotype. PE 22-28 blockade of this overexpression may limit its consequences. Neurogenesis and synaptogenesis induction would also support recovery.
Post-stroke depression affects 20 to 50% of stroke survivors with worsened recovery and increased mortality, and conventional antidepressants achieve remission in only approximately 30% of PSD patients. This is a genuine high-need clinical target where novel mechanisms have clear rationale.
Preclinical evidence for a genuinely important unmet clinical need. The MCAO model is standard but has a poor translation track record: the history of agents working in MCAO that fail in humans is longer than for almost any other preclinical neuroscience model. No independent replication of PE 22-28 stroke and PSD results has been published.
PE 22-28 treatment in mice produced approximately a doubling of BrdU-positive cells in the hippocampus after 4 days. Synapsin and PSD-95 were increased in mouse cortical neurons. BDNF was upregulated in hippocampal tissue. These are established markers of neuroplasticity and synaptogenesis, associated with improved learning and memory in rodent models.
However, no rodent cognitive behavioral tests have been published specifically for PE 22-28 (no Morris water maze, novel object recognition, or contextual fear conditioning data). The cognitive enhancement claims in wellness community content are extrapolated from synaptogenesis and BDNF marker data, not from direct cognitive performance testing in any animal.
Neuroplasticity markers are elevated in PE 22-28 mouse studies, consistent with the TREK-1 mechanism. The leap from increased PSD-95 expression in mouse cortical neurons to enhanced human cognitive performance requires validated cognitive behavioral studies in animals and then human trials, neither of which has been conducted. The cognitive enhancement framing in wellness content is premature.
BDNF-mimicking peptide with antidepressant effects in rodents. No human data.
No validated human dosing protocol exists. Researcher community reports of 50 to 100 mcg/day subcutaneous injection are extrapolated from mouse mcg/kg data with allometric scaling assumptions and have not been validated by any pharmacokinetic study. No FDA approval, no compounding authorization. Any human use exists entirely outside any regulatory or clinical framework. No published human pharmacokinetic studies exist characterizing absorption, distribution, or CNS penetration.
Among neurologically-targeted peptides in this series, PE 22-28 is unique as a potassium channel antagonist antidepressant. Semax and Selank have more human data from Russian clinical practice (limited GCP quality) and operate via BDNF upregulation and GABAergic modulation respectively. Cerebrolysin has Phase 3 RCT data. Dihexa had a compelling angiotensin-related cognitive mechanism but its foundational paper was retracted in 2025. PE 22-28 has the most mechanistically intact preclinical antidepressant evidence in this neurological subset, and the least human data. It is arguably the most compelling candidate for a first-in-human trial that does not yet exist in this series.
PE 22-28 has no human safety data of any kind. The following reflects preclinical mouse findings only.
In mouse studies at pharmacologically active doses (3.2 to 40 mcg/kg), PE 22-28 and its analogs produced no observable systemic toxicity, no organ toxicity signals, no seizure activity, no cardiac dysfunction, no effects on pain thresholds, and no impact on glucose homeostasis. The absence of seizure-promoting effects is notable: TREK-1 gene deletion in mice increases seizure susceptibility, but pharmacological TREK-1 blockade with spadin and analogs does not replicate this phenotype.
A cardiovascular concern is theoretically warranted: TREK-1 is expressed in the heart and plays a role in atrial fibrillation, pulmonary arterial hypertension, and ventricular arrhythmia in preclinical models. Moha Ou Maati et al. (2012) characterized cardiac safety of parent spadin and found no cardiac dysfunction at antidepressant doses. This result is extrapolated to PE 22-28 by analogy but is not directly confirmed in published literature.
No formal toxicology package has been published for PE 22-28 (no ICH S7A/S7B cardiovascular safety pharmacology, no mutagenicity studies, no repeat-dose toxicology). These would be prerequisites for an IND application. The absence of reported adverse events in preclinical data should not be interpreted as confirmed safety in humans.
PE 22-28 has the most mechanistically interesting preclinical antidepressant story in this research series. The TREK-1 target is well-validated (Nature Neuroscience, PLoS Biology), the compound is 300 to 500 times more potent than its parent, it induces hippocampal neurogenesis in 4 days where SSRIs take 21 days in the same models, and it is selective for TREK-1 over related K2P channels. The biomarker evidence showing reduced endogenous PE in MDD patients adds human-relevant support to the TREK-1 hypothesis without constituting therapeutic evidence for PE 22-28 specifically.
None of that changes what the evidence tier says: Tier 4. All therapeutic evidence is preclinical, from a single research group. No independent academic group has published PE 22-28 behavioral replication. No human has received the compound in a clinical trial. No formal safety package has been published.
The reasons this remains entirely preclinical despite 15 years of research on the spadin series are instructive: blood-brain barrier penetration of short peptides in humans requires specific validation; the forced swim test and novelty suppressed feeding test have a poor track record predicting human antidepressant response; and commercial development of a compound derived from an endogenous naturally occurring peptide faces substantial patent protection challenges that reduce industry interest in sponsoring Phase 1 trials.
For researchers: the TREK-1 mechanism is scientifically credible, the compound is potent and specific, and a first-in-human trial would be a significant event in neuropsychopharmacology. Until that happens, compelling preclinical data cannot substitute for evidence of human safety or efficacy.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use